Lineage Cell Therapeutics, Inc. 13D and 13G filings for OncoCyte Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-01-08 5:00 pm Sale | 2021-01-07 | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 164,870 4.900% | -48,425 (-22.70%) | Filing |
| 2020-04-27 5:28 pm Sale | 2020-04-23 | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 213,295 6.300% | -88,763 (-29.39%) | Filing |